title: A prospective clinical study on the pathogenesis of multiple organ failure in severely burned patients.
abstract: This study has shown that multiple organ failure (MOF) is one of the major causes of death in patients with severe burns. Both the plasma and visceral levels of TXB2 and the TXB2/6-keto-PGF1 alpha ratio were significantly increased. The changed plasma levels of TXB2 and the TXB2/6-keto-PGF1 alpha ratio paralleled the deterioration of the general condition in MOF patients. The circulatory platelet aggregation ratios (CPAR) in the MOF patients initially declined then dropped profoundly at 5-7 days postburn, indicating more microaggregate formation. CPK, LDH and GOT had increased markedly by 1 day, were elevated further at 2-3 days, and remained at supranormal levels for the first 7 days postburn. Degeneration, destruction, oedema, haemorrhage and thrombosis were observed in tissues from patients who died due to heart, lung, renal and hepatic failure. Clinically, 13 of the 16 MOF cases developed organ failure and 11 died between 3 and 7 days postburn. These findings confirmed that the increases of TXA2 and the TXA2/PGI2 ratio in plasma and visceral tissues can be an important factor in the genesis and development of postburn MOF.
authors.affiliation: Burn Institute, Southwestern Hospital, Third Military Medical College of PLA, Chongqing, Sichuan, China.
authors.forename: Y S
authors.initials: YS
authors.lastname: Huang
authors.forename: A o
authors.initials: Ao
authors.lastname: Li
authors.forename: Z C
authors.initials: ZC
authors.lastname: Yang
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism*; D000293:Adolescent; D000328:Adult; D001830:Body Surface Area; D002056:Burns / Q000150:complications* / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000209:etiology* / Q000378:metabolism; D011446:Prospective Studies; D012769:Shock / Q000378:metabolism; D013928:Thromboxane A2 / Q000378:metabolism*
chemical_list: D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha